NDA 214133 · Strongbridge
Recorlev
Levoketoconazole · Oral · Cortisol Synthesis Inhibitor
OrphanLast checked: Nov 20, 2026Latest source record: Aug 16, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Dec 30, 2021
Approved uses
1
Original approval plus efficacy supplements
Registered trials
6
3 Phase 3, 0 recruiting
FAERS reports
756
438 serious, 14 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HEPATOTOXICITY AND QT PROLONGATION Hepatotoxicity • Cases of hepatotoxicity with a fatal outcome or requiring liver transplantation have been reported with use of oral ketoconazole. Some patients had no obvious risk factors for liver disease. Serious hepatotoxicity has been reported in patients receiving RECORLEV [see Warnings and Precautions ( 5.1 )]. • RECORLEV is contraindicated in patients with cirrhosis, acute liver disease or poorly controlled chronic liver disease, recurrent symptomatic cholelithiasis, a prior history of drug induced liver injury due to ketoconazole or any azole antifungal therapy that required discontinuation of treatment, or extensive metastatic liver disease [see Contraindications ( 4 ), Warnings and Precautions ( 5.1 )]. • Evaluate liver enzymes prior to and during treatment. Interrupt RECORLEV treatment immediately if signs of hepatotoxicity occur...
What it is approved for
From the label in effect Mar 10, 2026.
RECORLEV is indicated for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Limitations of Use RECORLEV is not approved for the treatment of fungal infections. The safety and effectiveness of RECORLEV for the treatment of fungal infections have not been established. RECORLEV is a cortisol synthesis inhibitor indicated for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative ( 1 ) Limitations of Use RECORLEV is not approved for the treatment of fungal infections ( 1 )
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 30, 2021 Original approval · Type 2 - New Active Ingredient OrphanLetterLabelMedication Guide
1 products under this application
- RECORLEV · LEVOKETOCONAZOLE 150MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Levoketoconazole" as an intervention, any sponsor and status, largest first.
- Treatment for Endogenous Cushing's SyndromePivotal-lookingCompleted
Cortendo ABIndustry
NCT01838551 · 94 participants · Start Aug 2014 · Primary completion Apr 2018
Drug: Levoketoconazole · For: Endogenous Cushing's Syndrome
Sites: Los Angeles, California; Baltimore, Maryland; Boston, Massachusetts · 42 sites in all
- A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.Pivotal-lookingCompleted
Cortendo ABIndustry
NCT03277690 · 84 participants · Start Sep 26, 2017 · Primary completion Jun 30, 2020
Drug: Levoketoconazole; Placebo · For: Endogenous Cushing's Syndrome
Sites: Los Angeles, California; Fort Lauderdale, Florida; Atlanta, Georgia · 45 sites in all
- Open-label Treatment in Cushing's SyndromePivotal-lookingCompleted
Cortendo ABIndustry
NCT03621280 · 51 participants · Start Jan 7, 2019 · Primary completion Dec 31, 2022
Drug: Levoketoconazole · For: Cushing Syndrome; Cushing Disease
Sites: Fort Lauderdale, Florida; Atlanta, Georgia; St Louis, Missouri · 30 sites in all
Cortendo ABIndustry
NCT04212000 · 34 participants · Start Dec 16, 2019 · Primary completion Jan 18, 2020
Drug: Levoketoconazole; Ketoconazole · For: Healthy
Sites: Salt Lake City, Utah
Cortendo ABIndustry
NCT03880825 · 32 participants · Start Mar 28, 2019 · Primary completion May 3, 2019
Drug: Metformin 500 mg Oral Tablet; Levoketoconazole 150 - 600 mg (BID) · For: Healthy Subjects
Sites: Miami, Florida
Cortendo ABIndustry
NCT03768388 · 22 participants · Start Nov 30, 2018 · Primary completion Dec 24, 2018
Drug: levoketoconazole · For: Healthy Subjects
Sites: Miami, Florida
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue256
- nausea222
- headache181
- dizziness117
- vomiting105
- diarrhoea94
- pain87
- weight decreased84
- malaise79
- insomnia77
- arthralgia73
- asthenia73
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2022 | 49 |
| 2023 | 88 |
| 2024 | 92 |
| 2025 | 145 |
| 2026 | 382 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Recorlev (Levoketoconazole)
2024 spending
$29.7M
Beneficiaries
228
1,112 claims
Per beneficiary
$130,047
$376.77 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $2,398,497 |
| 2023 | $9,811,453 |
| 2024 | $29,650,764 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Levoketoconazole in the Treatment of Patients With Cushing's Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study.
Pivonello R, Elenkova A, Fleseriu M, et al. · Front Endocrinol (Lausanne) 2021 · Clinical Trial, Phase III, Multicenter Study
- Levoketoconazole in the treatment of patients with endogenous Cushing's syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS).
Pivonello R, Zacharieva S, Elenkova A, et al. · Pituitary 2022 · Randomized Controlled Trial, Clinical Trial, Phase III
- Levoketoconazole treatment in endogenous Cushing's syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes.
Fleseriu M, Auchus RJ, Greenman Y, et al. · Eur J Endocrinol 2022 · Clinical Trial
- Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial.
Fleseriu M, Pivonello R, Elenkova A, et al. · Lancet Diabetes Endocrinol 2019 · Clinical Trial, Phase III, Multicenter Study
- Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies.
Fleseriu M, Castinetti F · Pituitary 2016 · Systematic Review
- Effectiveness of Medical Treatment of Cushing's Disease: A Systematic Review and Meta-Analysis.
Simões Corrêa Galendi J, Correa Neto ANS, Demetres M, et al. · Front Endocrinol (Lausanne) 2021 · Meta-Analysis, Systematic Review
Sponsor: Strongbridge
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.